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Abstract
Background: Paraquat (1, 1-dimethyl-4, 4-bipyridium dichloride; PQ) causes neurotoxicity, especially dopaminergic
neurotoxicity, and is a supposed risk factor for Parkinson’s disease (PD). However, the cellular and molecular
mechanisms of PQ-induced neurodegeneration are far from clear. Previous studies have shown that PQ induces
neuroinflammation and dopaminergic cell loss, but the prime cause of those events is still in debate.
Methods: We examined the neuropathological effects of PQ not only in substantia nigra (SN) but also in frontal
cortex (FC) and hippocampus of the progressive mouse (adult Swiss albino) model of PD-like neurodegeneration,
using immunohistochemistry, western blots, and histological and biochemical analyses.
Results: PQ caused differential patterns of changes in cellular morphology and expression of proteins related to
PD and neuroinflammation in the three regions examined (SN, FC and hippocampus). Coincident with behavioral
impairment and brain-specific ROS generation, there was differential immunolocalization and decreased expression
levels of tyrosine hydroxylase (TH) in the three regions, whereas a-synuclein immunopositivity increased in
hippocampus, increased in FC and decreased in SN. PQ-induced neuroinflammation was characterized by area-
specific changes in localization and appearances of microglial cells with or without activation and increment in
expression patterns of tumor necrosis factor-a in the three regions of mouse brain. Expression of interleukin-1b
was increased in FC and hippocampus but not significantly changed in SN.
Conclusion: The present study demonstrates that PQ induces ROS production and differential a-synuclein
expression that promotes neuroinflammation in microglia-dependent or -independent manners, and produces
different patterns of dopaminergic neurotoxicity in three different regions of mouse brain.
Keywords: Paraquat, a?α?-synuclein, tyrosine hydroxylase, tumor necrosis factor-a?α?, interleukin-1b?β?, substantia
nigra, frontal cortex, hippocampus
Background
Several studies in rodent models have indicated that
Paraquat (1, 1-dimethyl-4, 4-bipyridium dichloride; PQ)
an environmental herbicide/pesticide, causes neurotoxi-
city through the generation of reactive oxygen species
(ROS) and formation of apoptosis-related molecules. PQ
promotes intracellular generation of ROS via three
distinct pathways: (1) reduction of PQ by NADPH-cyto-
chrome P450 reductase and a subsequent redox cycle
with involvement of super oxide dismutase (SOD) and
glutathione pools, (2) inhibition of mitochondrial elec-
tron transport chain, and (3) interaction with other
enzymes such as nitric oxide synthase (cytosolic),
NADPH oxidase (plasma membrane), thioredoxin
reductase (cytosolic form, Trx 1), and xanthine oxidase
[1]. PQ-induced oxidative stress has been reported to be
linked to endoplasmic reticulum stress-signaling path-
ways and subsequent formation of caspase-dependent
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shown to induce neuronal oxidative stress through acti-
vation of glial cells [4]. However the exact mechanism
of neuronal cell death after PQ administration in rodent
models is far from clear. Although carrier-mediated
(neutral amino acid transporter carriers, such as LAT-1,
which transports L-valine and L-phenylalanine) trans-
port of PQ across the blood-brain barrier (BBB) has
been reported in rodent studies [5,6], there is contro-
versy regarding the entry of PQ through BBB, the cellu-
lar metabolism of PQ, and the mechanism of its toxicity
in brain of non-human primates and human beings
[4,7].
Because of its close structural similarity to 1-methyl-4-
phenylpyridinium (MPP+, the active metabolite form of
MPTP), Paraquat has been suggested to be a risk factor
for PD. Systemic administration of Paraquat to adult
mice results in a significant decrease in substantia nigra
dopaminergic neurons, a decline in striatal dopamine
nerve terminal density, and a neurobehavioral syndrome
characterized by reduced ambulatory activity. Prolonged
exposure to paraquat leads to a remarkable accumula-
tion of a-synuclein-like aggregates in neurons of the
substantia nigra pars compacta in mice [8].
PQ-induced dopaminergic neuronal cell death in the
s u b s t a n t i an i g r a( S N )h a sb e e nf o u n dt ob el i n k e dw i t h
aggregation of a-synuclein, in addition to mitochondrial
dysfunction and oxidative stress. PQ induces a-synu-
clein aggregation through protein up-regulation [9,10].
PQ-induced oxidative stress could facilitate a-synuclein
association by altering the biophysical properties of the
protein, by proteosomal dysfunction, and/or by impair-
ing mechanisms of protein degradation within neurons
[4,9,11]. In the Paraquat-induced mouse model of PD,
microglial activation and pesticide exposure act synergis-
tically, and the susceptibility of dopaminergic neurons to
t o x i ci n j u r yi sd r a m a t i c a l l ye x a c e r b a t e db yu n d e r l y i n g
inflammatory processes [12]. PQ induces neuroinflam-
mation and microglial activation indirectly through fac-
tors released from neurons or astrocytes [13]. PQ
induces nigral astrocytosis and microgliosis, the latter
showing a reactive phenotype with increased numbers
of macrophage antigen complex-1-immunoreactive cells
(a marker for activated microglial cells) [14,15]. Dopami-
nergic neurons in the substantia nigra and ventral teg-
mental area have different susceptibilities to damage by
PQ toxicity [16], and major unanswered questions
include whether the protein aggregates cause the selec-
tive loss of dopaminergic neurons in the substantia
nigra that underlies the clinical symptoms and whether
neuroinflammation is a consequence or a cause of nigral
cell loss [17].
Apart from SN, PQ can also damage hippocampal
neurons of mouse brain through oxidative stress-
induced mitochondrial dysfunction [18]. PQ also
induces cell loss in locus coeruleus, in the area in which
catecholaminergic neurons are located [19]. In vitro stu-
dies have shown that PQ induces apoptosis of cultured
rat cortical cells [20]. It is not clear whether PQ-induced
dopaminergic cell death is selective or if other cell types
are similarly affected [18,4,21] in other regions of brain
such as frontal cortex (which is primarily responsible for
cognitive and motor responses) and hippocampus
(which is primarily responsible for learning, cognition
and memory).
Studies with rodent models have suggested that PQ is
a potential risk factor for Parkinson’sd i s e a s e( P D ) .P Q -
induced neurotoxicity and PD pathology show molecular
similarities including protein aggregation [22], neuroin-
flammation [23], oxidative stress [24], mitochondrial
dysfunction [25]and caspase activation [26]. However, a
role for PQ in causing Parkinsonism in non-human pri-
mates and human beings is uncertain due to a lack of
experimental and clinical evidence.
The exact mechanism of PQ-induced neurotoxicity
i s ,t h e r e f o r e ,s t i l li nd e b a t e .A nu n d e r s t a n d i n go ft h e
molecular basis of PQ-induced neurotoxicity could
provide valuable insights into neurodegenerative pro-
cesses in mammalian brain. In the present study, we
sought to define PQ-induced changes in molecular
events associated with dopaminergic neurodegenera-
tion in three regions of brain: SN, hippocampus, and
frontal cortex (FC). Although PQ toxicity causes dopa-
minergic cell death in SN, the site of origin of dopami-
nergic innervation in brain, an effect of PQ on
dopaminergic neuronal processes in hippocampus and
FC has not been established. PQ toxicity and PD-like
motor dysfunction/cognitive impairment both are
accompanied by neuronal damage in hippocampus and
frontal cortex. The main objective of our present study
was to assess possible molecular links between PQ-
induced dopaminergic neurotoxicity, alteration of a-
synuclein status, and microglial activation in three
regions of brain. Dopaminergic neurotoxicity was
determined using the neuronal markers FOX-3, tyro-
sine hydroxylase (TH; the rate-limiting enzyme of
DOPA synthesis) and DOPA decarboxylase (the
enzyme that catalyzes decarboxylation of L-dopa to
dopamine). The microglial marker Iba-1, the microglial
activation marker Mac-1, the histological feature of
microglial aggregation, and microglial expression of
the cytokines interlukin-1ß (IL-1ß) and tumor necrosis
factor- a (TNF-a) were determined in the three brain
regions. The study was extended with tocopherol (an
ROS scavenger) supplementation followed by PQ treat-
ment to assess PQ-induced ROS generation and its
possible impact on alterations in a-synuclein status
and microglial activation.
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Materials
Paraquat dichloride (PQ; 1,1’-Dimethyl-4,4’-bipyridinium
dichloride hydrate) and a-tocopherol were purchased
f r o mS i g m aA l d r i c h ,I n c .( S t .L o u i s ,M O ) .A m o n gt h e
primary antibodies used, anti-tyrosine hydroxylase
mouse monoclonal antibody was purchased from Cal-
biochem (EMD4Biosciences, NJ, USA); rabbit polyclonal
anti-TNF-a and anti-IL-1b, and mouse monoclonal
anti-a-synuclein were procured from Cell Signaling
Technology, Inc. (Danvers, MA, USA); mouse monoclo-
nal anti-FOX3, anti-DOPA decarboxylase, goat polyclo-
nal anti-Iba 1, and rabbit polyclonal anti-Mac1 were
procured from Abcam plc (Cambridge, UK). The sec-
ondary antibodies goat anti-rabbit IgG–HRP (horserad-
ish peroxidase) and rabbit anti-mouse IgG–HRP, and a
DAB developing system (for immunohistochemistry)
were purchased from Bangalore GeNei Pvt. Ltd. (Banga-
lore, India). FITC-conjugated secondary mouse anti-goat
antibody was purchased from Santa Cruz biotechnolo-
gies (DA, USA). Hematoxyline and eosin were obtained
from Merck Specialties Private Limited (Mumbai, India)
and the remaining chemicals were purchased in analyti-
cal grade of highest purity (India).
Animals
Adult male Swiss albino mice weighing ~28 gm each
(22-24 weeks of age; five mice in each group) were
obtained from the National Institute of Nutrition
(Hyderabad, India). All animals were housed individually
for at least one week prior to experiments in an animal
facility (maintained at 25 [ ± 2]°C with 55 [ ± 5]% rela-
tive humidity and 12-hr light/dark cycle) located at the
Animal Housing Unit in the Department of Zoology,
University of Calcutta. All animals were provided rodent
chow obtained from National Institute of Nutrition
(Hyderabad, India) and filtered water ad libitum.A l l
animal experiments were performed following “Princi-
ples of laboratory animal care” (NIH publication No. 85-
23, revised in 1985) as well as specific Indian laws on
“Protection of Animals” under the provision of author-
ized investigators. The protocols were approved by the
Institutional Animal Ethics Committee at the University
of Calcutta.
PQ administration and supplementation with a-
tocopherol
A total of 50 mice received intraperitoneal (i.p) injec-
tions of PQ at different concentrations [5, 10, 20, 40, 80
mg/kg body weight (b.w.)] in a total volume of 0.2 ml,
twice a week for four consecutive weeks to determine
the LD50 dose (n = 10 for each dose of PQ). Thereafter,
based on this data, new sets of mice were provided with
sublethal doses (10 mg PQ/kg b.w.) twice a week for 4
weeks. Mice were randomly divided into 4 groups com-
prising (A) vehicle/saline (0.9% NaCl)-treated control (n
= 6), (B) PQ-treated (n = 6), (C) a-tocopherol–supple-
mented. PQ-treated (n = 6), and (D) a-tocopherol-sup-
plemented, vehicle/saline-treated controls (n = 6) for the
experiments to be performed.
a-Tocopherol was supplemented to mice that had
been treated previously with PQ, 10 mg/kg b.w. for four
weeks. a-Tocopherol was injected intraperitonealy at 20
mg/kg b.w. for five consecutive days after the last dose
of PQ (up to day six) and sacrificed thereafter on day
seven.
General health and gross motor functions assessment
Mice were observed twice daily during the first week of
injections (10 mg PQ/kg b.w. for each mouse) and daily
thereafter. General health and gross motor functions
were assessed by observing in-cage behavior and during
brief gentle handling to check for rigidity (hunched pos-
ture and increased tail tone), bradykinesia (slowed
movement and/or absence of rearing), dystonia
(clenched paws), autonomic signs (piloerection) and
stopped movement (akynesia). Additionally, body
weights were checked prior to and each week after PQ
administration. Simple behavioral tests in control and
PQ-treated mice were performed three days after the
last injection. Asymmetry in body posture and gait
abnormalities were tested with the curling test and the
footprint test, respectively. The curling test evaluates
any asymmetry in body posture [27]. The mice were
lifted gently 2-3 cm above the bedding for 5 seconds
and any ipsilateral deviation from its vertical body axis
of 10° or greater was recorded. The test was repeated
three times for each animal.
For the footprint test mice were placed in a 5-cm-
wide, 55-cm-long corridor. The floor of this corridor
was covered with white absorbant paper. The animals
were first trained to pass straight forward through the
corridor. After this training, the paws were colored with
different colors (red for the forepaws and violet for the
hindpaws), and the mice were then placed into the cor-
ridor. Step frequency and stride length were determined
with the program Footprints version 1.22 [27].
Tissue handling
On the 7
th day after the final dosing with PQ, mice in
each group were euthanized by over-dose of sodium
t h i o p e n t o n e( M a n c u r eD r u g sP r i v a t eL t d . ,M u m b a i ,
India) and brain tissues harvested for analyses as
described in the assays below. The animals used in
behavioral studies were same animals that were sacri-
ficed thereafter for brain tissue analysis.
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Animals were deeply anesthetized by overdose of
s o d i u mt h i o p e n t o n e( M a n c u r eD r u g sP r i v a t eL t d . ,
Mumbai, India) and were sacrificed by decapitation.
B r a i n sw e r er e m o v e di m m e d i a t e l ya n dw a s h e di ni c e -
cold phosphate-buffered saline (PBS, pH 7.4). Then, the
tissues were cut into two equal halves along the longitu-
dinal fissure. The tissues were fixed for 24 hours in buf-
fered formaldehyde solution (10% in PBS) at room
temperature, dehydrated by graded ethanols (50-100%)
a n de m b e d d e di np a r a f f i n( M e r c k ,s o l i d i f i c a t i o np o i n t
60–62°C). Tissue sections (thickness 5 μm) were then
deparaffinized with xylene, rehydrated with graded alco-
hols (100%-50% ethanol), stained with eosin/haematoxy-
lin (Merck, Mumbai, India) and mounted in DPX resin
(Merck, Mumbai, India). Images were captured using an
Olympus BX51 microscope attached to an Olympus
DP70 camera (U-TVO 63 × C; Olympus Corp., Tokyo,
Japan) having both 40× and 100× (wide zoom) lenses.
Immunohistochemistry
Sagittal brain sections (5 µm thick) were cut from paraf-
fin-embedded brain tissue and mounted on positively-
charged Super frost slides (Export Mengel CF, Menzel,
Braunschweig, Germany). Tissues were deparaffinized,
dehydrated through graded alcohols, and then endogen-
ous peroxidase was quenched in a 3% hydrogen perox-
ide solution for 20 minute at room temperature.
Background staining was then inhibited with 5% bovine
serum albumin [BSA] (Sisco Research Laboratories Pvt.
Ltd. [SRL], Mumbai, India) for 30 minutes at room tem-
perature to avoid nonspecific binding of IgG. Excess
liquid was drained and the sections were incubated in a
humid chamber overnight at 4°C with primary antibo-
dies (diluted 1:50 in solution containing 5% BSA). The
following specific primary antibodies were used for sepa-
rate cases:,anti-IL-1b (mouse polyclonal), anti-TNF-a
(mouse polyclonal), and anti-a-synuclein (mouse mono-
clonal) (Cell Signaling Technology, Inc. [Danvers, MA,
USA]), as well as anti-tyrosine hydroxylase (mouse
monoclonal) (Calbiochem [EMD4Biosciences, NJ, USA])
for positive controls (data not shown). After three
washes in PBS-T, sections were sequentially incubated
in horseradish peroxidase (HRP)-conjugated anti-sera
specific for those antigens and were diluted at a 1:30
ratio in Tris-buffered saline containing 0.3% Triton-X
and 0.5% blocking agent for 2 hours at room tempera-
ture. Immunoreactive complexes were then detected
using a DAB system (Merck Specialties). Sections were
then counterstained briefly in hematoxylin, dehydrated
through graded alcohols (70%, 95%, 100%), cleared in
xylenes, and coverslipped with DPX mounting medium.
Slides that received no primary antibody served as nega-
tive controls. Images were captured using a U-TVO 63
× C microscope (Olympus Corp., Tokyo, Japan) having
both 40× and 100× (wide zoom) lenses.
Preparation of cell lysates
Different brain regions – hippocampus, frontal cortex,
and SN – were dissected out immediately after dissec-
tion of sagittal sections of whole brain [28]. Tissues
were homogenized in ice-cold RIPA lysis buffer (150
mM sodium chloride, 1.0% TritonX-100, 50 mM Tris
pH 8.0, 0.01% SDS, 0.5% sodium deoxycholate) contain-
ing 1 mM PMSF (phenylmethanesulfonylfluoride or
phenylmethylsulfonyl fluoride) (SRL, India), 1 μg/ml
aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin
(Sigma-Aldrich Inc., USA) that were added fresh prior
to cell lysis. The samples were sonicated and incubated
on ice for 30 min, and centrifuged 3 times at 14,000
rpm for 15 min at 4°C. A portion of the supernatant
was reserved for protein determination using the Brad-
ford reagent (Sigma-Aldrich Inc., USA) and subsequent
measurement of absorbance was done at 595 nm in a
UV-1700 PharmaSpec, Shimadzu spectropho-tometer
(Shimadzu Scientific Instruments, Columbia, MD). The
remaining supernatant was stored at -20°C.
Western blot analysis
Tissue lysates were diluted in sample buffer (0.312 mM
Tris-HCl [pH 6.8], 50% glycerol, 10% SDS, 25% b-mer-
captoethanol, and 0.25% bromophenol blue) at a final
protein concentration of 5 μg/μl, and were then boiled
at 100°C for 5 minutes. Aliquots of each sample (10 μl
containing 50 μg protein) were loaded into dedicated
wells of 9-12% polyacrylamide gels and separated by
electrophoresis for 3 h at 100 V. Proteins were trans-
ferred to polyvinylidene difluoride membrane (Amer-
sham Biosciences, Piscataway, NJ) for 1.5 h at 300 mA.
After blocking of nonspecific binding with 5% nonfat
dry milk in TBST, the membranes were then probed
with the following primary antibodies: anti-tyrosine
hydroxylase (mouse monoclonal; 1: 2000 dilution), anti-
TNF-a,a n t i - I L - 1 b (rabbit polyclonal; 1: 1000 dilution),
anti-a-synuclein (mouse monoclonal; 1: 1500 dilution)
anti-FOX3, anti-DOPA decarboxylase (mouse monoclo-
nal; 1: 2000 dilution), anti-Iba1 (goat polyclonal; 1: 2500
dilution), anti-Mac1 (rabbit polyclonal; 1: 2000 dilution)
and incubated overnight at 4°C. The membranes were
washed 3 times with Tris-buffered saline-0.01% (v/v)
containing Tween-20 at room temperature for 15 min-
utes and then incubated with alkaline phosphatase (AP)-
conjugated secondary antibodies (anti-rabbit, anti-goat
and anti-mouse IgG; diluted 1:1000) with TBST for 2 h
at room temperature. The membranes were then devel-
oped with NBT/BCIP (nitroblue tetrazolium chloride/5-
bromo-4-chloro-3-indolyl-phosphate; Hi-Media, Mum-
bai, India). Band intensity of the detected protein was
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Rad Laboratories, USA). b-Actin was also analyzed on
each membrane for confirmation of gel sample loading
(i.e., based on constitutive expression).
Immunofluorescence
The immunofluorescence procedure was carried out on
sections incubated in blocking buffer (0.3-0.5% Triton
X-100, 5% BSA in TBS) for 30 min at room temp fol-
lowed by an overnight incubation with the primary anti-
body Iba1 (goat polyclonal; 1: 50 dilution) in blocking
buffer at 4°C,. After three washes in TBS-T, primary
antibody was revealed by incubating the sections in
FITC-conjugated anti-sera specific for those antigens
and diluted at a 1:30 ratio in Tris-buffered saline con-
taining 0.3% Triton-X and 0.5% blocking agent for 2
hours at room temperature followed by TBS washing.
The tissue sections were counterstained with a nuclear
counterstain (DAPI by Vector Laboratories Inc. Burlin-
game, CA, USA) and mounted with DPX resin. Images
were captured in a U-TVO 63 × C microscope (Olym-
pus Corp., Tokyo, Japan) having both 40× and 100×
(wide zoom) lenses.
Stereological cell counting
Stereological methods were used for quantification of
cells present in stained tissues as previously described
[29]. Briefly, tissue was visualized with an Olympus U-
TVO 63 × C microscope and Micro Bright Field CX
9000 camera. Cell counting was done for both side of
the brain for each animal, and then right and left values
were added to generate a total DA substantia nigra neu-
ron count, in a total of five animals per experimental
group. The tissue was quantified using optical fractiona-
tors from MicroBrightField, with the software Stereo
Investigator (Ver.8). Estimated volumes (μm
3)o fT H -
negative zones were quantified using the cavalieri
method of unbiased stereology in the substantia nigra of
every third section. Also, expression of FOX 3-positive
cells was quantified in substantia nigra using the cava-
lieri method. Both immunostains were quantified with a
grid spacing of 200 μm using a 2×/0.06 objective. TH-
positive cells were also quantified within the area of the
substantia nigra pars compacta. The sampling site was
customized to count 200 cells per brain, and sampling
was done with error coefficients less than 0.07. For
counting TH-positive cells the counting frame (CF) was
70 × 70 with a virtual counting grid (CG) of 140 × 140.
For FOX3-positive cells CF and CG were the same as
for TH-positive cells.
Microglia-specific silver staining
Microglia-specific silver staining was performed as pre-
viously described [30]. Briefly, paraffin-embedded mouse
brain sections were deparaffinized with xyline followed
by rehydration in a series of graded (100%-50%) etha-
nols. After washing in distilled water, sections were
transferred for silver impregnation in 10% ammoniacal
silver nitrate solution for 3-4 seconds. After that, sec-
tions were transferred to a 10% formalin solution and
then washed with distilled water. The slides were then
fixed in 5% sodium thiosulfate solution for 2-5 minutes.
Sections were washed and then dehydrated in graded
alcohols and finally mounted in DPX (MERCK) for
microscopical studies. Images were captured in an
Olympus BX51 microscope attached with Olympus
DP70 camera (U-TVO 63 × C) (Olympus, USA).
Preparation of homogenatse for ROS scavenging enzyme
assay
A 10% tissue homogenate was prepared in 0.1 M phos-
phate buffer (pH 7.4) containing 0.1 M KCl. Enzyme
assays were performed in the supernatant obtained fol-
lowing centrifugation of the homogenate at 9000 × g for
10 min at 4°C.
Measurement of catalase activity
Catalase was measured usig the method described by
Sinha et al. (1972) [31]. In brief, an assay mixture con-
sisting of 0.01 M phosphate buffer (pH 7.0), 0.2 M
hydrogen peroxide and tissue homogenate was incu-
bated at 37°C for 1 min. The reaction was stopped by
addition of potassium dichromate (5% w/v) and acetic
acid. The remaining hydrogen peroxide was determined
by measuring chromium acetate after heating the assay
mixtures in a boiling water bath for 15 min. Absorbance
was read at 570 nm against control without hydrogen
peroxide. Enzymatic activity is expressed as μmol/min/
mg protein.
Estimation of glutathione S-transferase activity
Glutathione S-transferase was assayed spectrophotome-
trically by the method described by Pabst et al. (1974)
[32]with slight modifications. In brief, 150 μl homoge-
nate was mixed with 0.2 M phosphate buffer (pH 6.5).
The reaction was initiated by addition of 20 μl3 %
CDNB (1 chloro-2,4-dinitrobenzene). Optical density
was measured at 340 nm at intervals of 30 s for 3 min,
and activity was calculated as nM/min/mg protein.
Measurement of total cytosolic superoxide dismutase
Superoxide dismutase (SOD) was measured spectropho-
tometrically at 570 nm using the modified method of
Kakkar et al. (1984) [33]. In brief, an assay mixture con-
taining sodium pyrophosphate buffer (pH 8.3, 0.052 M),
phenazine methosulfate (186 μM), nitroblue tetrazolium
(300 μM), NADH (780 μM) and appropriately diluted
enzyme in a total volume of 3 ml was incubated at 37°C
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acetic acid. The reaction mixture was mixed vigorously
by adding n-butanol and was allowed to stand for 10
min before collection of the butanol layer. The intensity
of chromogen in the butanol was measured at 560 nm.
SOD activity was calculated as μmol/min/mg protein.
Statistical analysis
Values between groups were analyzed using single way
ANOVA. All values are shown as mean ± SEM, except
where otherwise indicated. Data were analyzed and
when appropriate, significance of the differences
between mean values was determined using Student’st -
test. Results were considered significant at p < 0.05.
Results
Effect of PQ on mice survival
To assess a permissible dose, different doses of PQ (5,
10 [34], 20 [35], 40 [36]and 80 mg PQ/kg b.w.) were
administered to mice twice a week over a 4-week period
based on previous reports. Experimental animals treated
w i t hP Qa tad o s eo f1 0m g / k gb . w .d i dn o ts h o wa n y
mortality through day 35, when they were sacrificed.
Survival decreased with greater increments of dosage:
50% and 80% of animals died at doses of 20 mg/kg b.w.
(within the first 15 days of treatment, after a total of 4
or 5 doses per recipient) and 40 mg PQ/kg b.w. (within
the first 8 days of treatment, after 1 or 2 doses per reci-
pient) treatments, respectively, and animals that were
treated with PQ at a concentration of 80 mg/kg b.w.
died after the first treatment. Therefore, further experi-
ments were performed using a dose of 10 mg PQ/kg b.
w. (a sublethal dose) (Figure 1).
Behavioral changes observed in PQ-treated (10 mg/kg b.
w.) mice
Motor performance deteriorated greatly in the treatment
group (10 mg/kg b.w.) of animals after two weeks of treat-
ment, and this deterioration was progressive over the next
several days. Several symptoms appeared, including out-
ward curvature of the spine (i.e. hunched posture like
kyphosis), piloerection, and twisting with repetitive move-
ment by involuntary contractions of muscle, called dysto-
nia. With additional days of PQ treatment, mice showed
reduction of progressive and spontaneous motor activity,
trembling, drooling, lassitude, clumsy limb activity and
even inactivity. After administration of the final dose and
before the day of sacrifice (day 35), the treatment group of
mice showed trembling, hypolocomotion, gazing, poly-
pnoea, arched back, stretched hind limbs, unstable gait,
tail hyperextension and irritability. To address the posture
and walking difficulties associated with neurodegeneration,
simple behavioral tests were performed three days after
the last injection in control and PQ-treated mice (Figure
2). It is clear that mice treated with 10 mg/kg b.w. PQ
exhibited severe postural instability, consistent with a uni-
lateral lesion. All of the mice in this group displayed ipsi-
lateral curling (Figure 2A). No asymmetry was observed in
the saline-treated control groups. Treated mice showed
gait impairment assessed by footprint patterns (Figure 2B),
in particular stride length and step frequency (Figure 2C
and 2D respectively). Irregular stride length in consecutive
steps was noted in PQ-treated animals.
ROS-scavenging enzymes (catalase, GST and SOD) activity
increased in all three regions of brain with sublethal as
well as lethal doses of PQ
It is evident that PQ causes neurotoxicity through the
generation of reactive oxygen species (ROS). Therefore,
to assess whether increased ROS levels are involved in
PQ-mediated neurotoxicity we assayed different ROS
scavenging enzymes – catalase, SOD and GST – in
three different brain regions of PQ-treated animals and
saline-treated controls.
Significant enhancements in catalase, GST and SOD
activities in all three areas of brain were observed in
PQ-treated animals (10 mg/kg b.w. dose), compared to
control animals. With other, lethal doses (20-80 mg PQ/
kg b.w.) catalase, GST and SOD activity was also
increased progressively with increment of dose over sal-
ine-treated controls (Figure 3A, B and 3C, respectively).
Supplementation with a-tocopherol in PQ-treated mice
decreased catalase, GST and SOD activities significantly
Figure 1 Dose-dependent effects of PQ on survival of mice and
identification of a sublethal dose of PQ. Survival of mice
indicates number of animals alive after PQ treatment. Intraperitoneal
injection of PQ with various doses (5, 10, 20, 40, 80 mg/kg b.w.)
caused death of animals at doses of 20, 40 and 80 mg/kg b.w. of
PQ. Animals treated with PQ at doses of 5 and 10 mg/kg b.w.
remained alive during the entire treatment period, and were
sacrificed after the final treatment as described in Methods. Animals
treated with 80 mg PQ/kg b.w. died within 8 hours of the 1
st dose.
Experiments were performed with 10 animals in each group. Error
bars represent animals that were alive on different days after
treatment of PQ with doses of 20 mg/kg b.w. and 40 mg/kg b.w.
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Page 6 of 22in all three regions of brain compared to mice treated
only with PQ (Figure 4A, B and 4C, respectively).
ROS scavenging enzyme activity in peripheral organs did
not change with sublethal doses but increased
progressively with increments of lethal doses of PQ
Our sublethal dose treatment (10 mg PQ/kg b.w.) pro-
duced substantially higher activity level of ROS-scaven-
ging enzymes, indicating high levels of ROS production
in all three regions of brain. To assess whether this sub-
lethal dose produces high peripheral level of ROS that
might damage peripheral tissues, we have estimated cat-
alase, GST and SOD activities in peripheral tissues like
lung, kidney, liver and blood plasma. There were
significantly increased activities of these ROS scavenging
enzymes in lungs, kidney, liver and blood plasma at all
three lethal doses but not with our experimental sub-
lethal dose (Figure 5A, B and 5C).
Tyrosine hydroxylase- and FOX 3-positive cell numbers
showed greatest decrease in SN after sublethal doses of
PQ, but not after lower sublethal or higher lethal doses
TH-positive and FOX3-positive neuronal cell numbers
decreased most significantly in SN of PQ (10 mg/kg b.
w.)-treated animals compared to controls (Figure 6A, B
and 6C). With other lethal and lower sublethal doses,
cell counts varied with significant decreases or no
changes compared to controls due to variable PQ
Figure 2 Symptoms of motor dysfunction in mice treated with a sublethal dose (10 mg/kg b.w.) of PQ. PQ caused severe postural
instability (A) and gait impairment (B). (A): The curling test evaluated asymmetry in body posture. There was severe hunched-back deviation
from the vertical body axis in PQ-treated animals. (B): Representative walking footprint patterns displayed irregular stride length in consecutive
steps in treated animals. Control animals followed a straight walking pathway, whereas treated animals deviated from the normal walking
pathway within a confined area. (C): Bar graph indicates differential stride length of consecutive steps in PQ-treated animals compared to
controls. (D): There were no significant differences in average number of steps (step frequency) for PQ-treated animals compared to vehicle-
treated controls. Values in figure C and D represent mean ± SEM (n = 3). Asterisk (*) indicates a significant change in stride length, p < 0.05
(Student’s t-test).
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Page 7 of 22Figure 3 Dose-dependent rise in activity of ROS-scavenging enzymes with PQ treatment in three regions of mouse brain. PQ treatment
with different doses of PQ (5, 10, 20, 40, 80 mg/kg b.w.) enhanced the activities of catalase (A), GST (B) and SOD (C) in SN, hippocampus and FC
of mouse brain. The activities of the enzymes indicate the status of ROS in tissues as described in the Results and Discussion sections. Enzyme
activity is presented as μmole/min/mg protein (for catalase and SOD activity) or as nmole/min/mg protein (for GST activity) as indicated in the
figures. Asterisks (*) indicate significant differences (p < 0.05, ANOVA) in values for different doses compared to controls. The same letter
indicates nonsignificant differences and different letters indicate significant differences (p < 0.05, Student’s t-test) between groups.
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Page 8 of 22exposure duration. With an 80-mg/kg b.w. dose there
were no changes in cell numbers compare to control
d u et ot h ef a c tt h a tt h e s em i c er e c e i v e do n l yas i n g l e
exposure to PQ.
Effects of PQ on changes in cellular morphology and
histology in SN, FC and hippocampus
Hematoxylin and eosin staining was performed on sagit-
tal sections of whole brain to observe histological and
morphological changes in SN, FC and hippocampus of
PQ-treated mice.
Pyknotic nuclei appeared in all three regions of brain
As there was a significant decrease in FOX 3- and TH-
positive cell counts in SN, we also evaluated PQ-induced
cellular changes in SN as well as in the other two brain
regions examined. Many pyknotic nuclei were found in
SN (Figure 7A). Frontal cortical areas also contained
many pyknotic nuclei (Figure 7B). Loss of neuronal cells
and formation of pyknotic nuclei appeared in different
areas, including hippocampal dentate gyrus, CA3 and
CA1 regions (Figure 7C) in PQ-treated mouse brain
compared to controls.
Lewy body-like formation in FC
Different types of Lewy body-like formations were found
in FC of PQ-treated mouse brain in the present study.
Rounded and oval-shaped Lewy body-like structures
with acidophilic central cores were present in FC (Figure
7B b, h). Irregular-shaped Lewy-like inclusions between
cellular processes appeared in pigmented cells of FC. At
the margin of dead cells, several Lewy bodies were also
observed (Figure 7B d). Pear-shaped Lewy inclusions
were also observed in FC (Figure 7B f). However, Lewy
bodies did not appear in FC of vehicle-treated control
mouse brains (Figure 7B a, c, e and g respectively).
Differential expression and localization of tyrosine
hydroxylase (TH) observed in SN, FC and hippocampus of
PQ-treated (10 mg/kg b.w.) mouse brain
FOX 3-positive and TH-positive neuronal cell counts
decreased, and the morphological appearance of cells var-
ied among different regions of brain in PQ-treated mouse
brain (as reported in Figure 6 and 7, respectively). As ROS
levels increased in all three regions of the brain, we
checked the status of the most vulnerable neuronal popu-
lations during oxidative stress conditions, i.e, dopaminer-
gic neurons in all three regions of the brain under
investigation. Studies with inmmunohistochemistry and
western blot techniques indicated differential expression
patterns for FOX3, DOPA decarboxylase, and immunolo-
calization of TH in all three areas of brain (Figure 8). The
immunoreactivity of TH shifted from nucleated to non-
nucleated areas in hippocampal regions (Figure 8C). Such
translocation of TH-immunoreactivity also appeared in FC
(Figure 8B) but not in SN (Figure 8A). Western blot analy-
sis indicated that FOX 3 expression levels decreased in SN
and in FC without any change in hippocampus of PQ-trea-
ted animals compared to controls (Figure 8D). TH immu-
noreactivity decreased significantly in all three regions of
brain in treated animals compared to controls (Figure 8E).
Figure 4 Tocopherol supplementation reduces PQ-induced
activation of ROS-scavenging enzymes. The activities of catalase,
GST and SOD (A, B and C) were measured in SN, FC and
hippocampus of mouse brain after PQ treatment. PQ treatment
increased enzyme activities significantly compared to saline-treated
controls. The values of enzyme activities after PQ treatment
followed by tocopherol supplementation remained significantly
lower than PQ-treated values, and were higher than saline-treated
control values. Tocopherol supplementation did not alter enzyme
activity compared to control values.
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Page 9 of 22Figure 5 Dose-dependent effects of PQ on ROS-scavenging enzymes in blood plasma and peripheral tissues. Lethal doses of PQ (20, 40,
80 mg/kg b.w.) enhanced the activities of catalase (A), GST (B) and SOD (C) in blood plasma and peripheral tissues (lung, liver and kidney) of
mice. The activities of these enzymes indicate the status of ROS in tissues and blood plasma. Enzyme activity is presented as μmole/min/mg
protein (for catalase and SOD activity) or as nmole/min/mg protein (for GST activity) as indicated in the figures. Asterisks (*) indicate significant
differences (p < 0.05, ANOVA) in values for different doses compared to controls. The same letter indicates nonsignificant differences and
different letters indicate significant differences (p < 0.05, student t-test) between groups.
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enzyme in dopamine biosynthesis) decreased significantly
in SN and FC of PQ-treated mouse brain compared to
that of non-treated brain, without any change in hippo-
campus (Figure 8F). Supplementation with a-tocopherol
did not result in any significant changes in FOX3, TH or
DOPA decarboxylase in any of the three regions studied
in PQ-treated mouse brain (data not shown).
Differential expression patterns of a-synuclein observed
in SN, FC and hippocampus of PQ (10 mg/kg b.w.)-
treated mouse brain
Differential patterns of a-synuclein expression are one of
the major markers of pesticide-induced neurodegenera-
tion, especially in Parkinson’s disease-like conditions. To
asses the hypothesis that increased ROS levels followed by
dopaminergic neurodegenera t i o ni nP Q - t r e a t e dm o u s e
brain are associated with a-synuclein status in brain, we
evaluated a-synuclein immunolocalization and immunor-
eactivity in SN, FC and hippocampus in treated mice
using immunohistochemistry and western blot. Immu-
noexpression of a-synuclein was decreased in SN of PQ-
treated mouse brain (Figure 9A), whereas immunoexpres-
sion of a-synuclein did not show any significant changes
in FC (Figure 9B). High levels of a-synuclein immunoreac-
tivity were found in hippocampal areas (CA1 and CA3) of
PQ-treated mouse brain compared to controls (Figure
9C). Some putative Lewy body-like structures with dense
a-synuclein immunopositivity also appeared in all three
regions of brain. Western blot analysis revealed that
Figure 6 Dose-dependent variable effects of PQ on dopaminergic cell counts in SN. Immunopositivity for FOX3 (A) and TH (B) represent
dopaminergic neuronal cells in SN during treatment of mice with different doses of PQ. Different doses of PQ (5, 10, 20, 40 and 80 mg/kg b.w.)
decreased cell counts variably in SN with a maximum observed effect at a PQ dose of 10 mg/kg b.w. (a sublethal dose) (C). Details of
immunohistochemistry and cell counting are described in Methods. Values are presented as mean ± SEM (n = 3). Asterisks (*) indicate significant
differences (p < 0.05, ANOVA) in cell counts for different doses compared to controls. The same letter indicates nonsignificant differences and
different letters indicate significant differences (p < 0.05, Student’s t-test) between groups.
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Page 11 of 22expression levels of a-synuclein decreased significantly in
SN, with no change in FC and significantly increased
expression in hippocampus (Figure 9D).
Supplementation with a-tocopherol did not result in
any significant changes in status of a-synuclein in any
of the three regions examined in PQ-treated mouse
brain (data not shown).
Changes of immunomodulatory molecules in PQ-treated
mice brain
To assess whether differential expression patterns of a-
synuclein in PQ-mediated neurotoxicity promotes
inflammation or not, we evaluated expression levels of
IL-1b and TNF-a in three different regions of brain.
Differential expression and localization of interleukin-1b (IL-
1b) in SN, FC and hippocampus
Differential expression patterns of the proinflammatory
cytokine IL-1b in the three regions of brain were
observed. Scattered and diffuse immunoreactivity for IL-
1b increased in SN, FC and hippocampus in the PQ-
treated groups compared to control groups (Figure 10A,
B and 10C respectively). Immunoreactivity for IL-1b
appeared outside of nucleated areas as patches. Some
microglia-like cellular structures surrounded by dense
immunoreactivity for IL-1b were observed in SN (Figure
10A). Western blot analysis showed that expression
levels for IL-1b increased significantly in hippocampus
and in FC during PQ treatment, without any significant
changes in SN (Figure 10D). Supplementation with a-
tocopherol did not produce any changes in status of
expression levels for IL-1b i na n yo ft h et h r e er e g i o n s
examined in PQ-treated mouse brain.
Tumor necrosis factor-a (TNF-a) is increased in SN, FC and
hippocampus of PQ (10 mg/kg b.w.)-treated animals
We also evaluated another inflammation marker, TNF-a,
in all three regions of PQ-treated mouse brain. Changes
in expression patterns for TNF-a in all three experimen-
tal areas were assessed using immunohistochemistry and
Figure 7 Histological and morphological changes in three regions of brain after PQ (10 mg/kg b.w.) treatment. Morphological
alterations in cells were observed by H&E staining in SN, FC and hippocampus of PQ-treated animal brains compared to controls. The detailed
procedure for staining is described in Methods. (A): Formation of pyknotic nuclei (black arrows) is found in SN of PQ-treated mouse brain, but
not in vehicle-treated controls. (B): Pyknotic nuclei (black arrows) and Lewy body-like structures (yellow arrows) appeared in FC of PQ-treated
mouse brain (b, d, f and h) but not in controls (a, c, e and g respectively). Lewy body-like structures of different shapes with acidophilic central
cores were found in four regions of frontal cortex. Lewy body-like structures were round-to-oval-shaped (b, h), or irregular-to-pear-shaped (d, f).
(C): Pyknotic nuclei were observed in the hippocampal regions dentate gyrus, CA3 and CA1 in PQ-treated animals (b, d, f respectively) but not
in control brain (a, c, e respectively). Magnification is 100× as indicated; scale bars = 10µm.
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Page 12 of 22Figure 8 Differential patterns of immunoreactivity of dopaminergic neuronal markers in brain after PQ (10 mg/kg b.w.) treatment.
Immunoreactive localization of TH was observed in SN, FC and different parts of the hippocampus (A, B and C, respectively). Densitometric
analysis of western blots for FOX3, TH and DOPA decarboxylase (D, E and F respectively) was performed to assess the status of dopaminergic
neurons in SN, FC and hippocampus. (A): TH-immunopositive neuronal cells (pigmented) and neurites were decreased in SN of PQ-treated mice
(b) compared to controls (a). (B): The cellular localization of TH immunoreactivity shifted from nucleated to non-nucleated neuritic areas in FC in
PQ-treated animals (b) compared to controls (a). (C): TH immunopositivity appeared in non-nucleated neuritic areas of the hippocampus
(dentate gyrus, CA3 and CA1) in PQ-treated animals (b, d, f respectively) compared to TH immunolocalization in nucleated areas in controls (a, c
and e respectively). (D and E): Expression levels of TH decreased in SN, FC and hippocampal areas of PQ-treated mice compared to respective
controls (E). PQ treatment caused significant decreases in expression levels of FOX 3 (D) and DOPA decarboxylase (F) in SN and FC, without any
changes of those parameters in hippocampus, compared to respective controls. b-Actin was used as a reference control in the western blots.
Data are presented as mean ± SEM. (n = 3). Asterisks (*) represent significant differences at a level of p < 0.05 (Student’s t-test) for the
densitometric analyses. Magnification of IHC images is 40×, and the scale bars = 40µm.
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Page 13 of 22western blot. Immunoreactivity for TNF-a increased in
all three regions of mouse brain treated with PQ com-
pared to control groups (Figure 11A, B, C). Immunoreac-
tivity of TNF-a appeared throughout the tissue sections,
including both nucleated and non-nucleated portions, in
all three experimental areas. However, this immunoreac-
tivity was highest surrounding nucleated cells in SN and
hippocampus. There were many microglia-like, large,
rounded structures surrounded by dense TNF-a immu-
noreactivity that appeared particularly in SN and hippo-
campus (Figure 11A, C) in PQ-treated mice brain. Some
small, rounded structures also appeared in FC but these
were very few in number (Figure 11B) in treated brain.
A p a r tf r o mt h a tu n k n o w nc e l l u l a rs t r u c t u r e ,d i s p e r s e d
and high immunoreactivity for TNF-a was observed in
nucleated areas of FC in PQ-treated mouse brain com-
pared to controls (Figure 11B). Western blot analysis
revealed significantly increased expression of TNF-a in
all three regions of brain in treated animals (Figure 11D).
Supplementation with a-tocopherol resulted in signifi-
cant decreases in immunoexpression of TNF-a in all
three regions of PQ-treated mouse brain compared to
PQ-treated mouse brain. Immunoreactivity of microglia-
like cells decreased in SN, FC and hippocampus of a-
tocopherol-supplemented, PQ-treated groups compared
to PQ-treated groups (Figure 12A, B and 12C). Western
blot analysis revealed that a-tocopherol supplementation
to PQ-treated mice decreased TNF-a expression levels
significantly in all three regions of brain compared to
PQ-treated mouse brain (Figure 12D).
Differential expression patterns of Iba1 as a microglial
marker and Mac 1 as a microglial activation marker
Microglial cells release immuno-inflammatory molecules
during injury in the central nervous system (CNS).
Increases in expression levels of IL-1b and TNF-a in all
Figure 9 Differential patterns of a-synuclein immunoreactivity after PQ (10 mg/kg b.w.) treatment. a-Synuclein immunolocalization in
SN, FC and hippocampus (A, B and C, respectively). (D) Densitometric analysis of western blot a-synuclein in SN, FC and hippocampus. (A): a-
Synuclein immunopositivity was dense in neuritic areas of SN in controls (a). a-Synuclein immunopositivity decreased in neuritic areas, and a few
pigmented nuclear structures (putative Lewy bodies) appeared (black arrows) in SN of PQ-treated animals (b). (B): a-Synuclein immunoreactivity
in neuritic areas of FC in PQ-treated and control animals. Large numbers of pigmented nuclear structures (putative Lewy bodies) appeared (black
arrows) in FC of PQ-treated brain (b), compared to vehicle-treated controls (a). (C): Non-nucleated areas (neuritic portions) but not nucleated
areas, of hippocampus showed a-synuclein immunopositivity in both control and treated animals. Dense a-synuclein immunoreactivity appeared
in non-nucleated areas of hippocampal regions CA3 and CA1 (b, d, respectively) in PQ-treated mouse brain compared to controls (a, c,
respectively). A few pigmented deposits (putative Lewy bodies) were found in non-nucleated areas of hippocampal regions of PQ-treated
animals, but not in respective controls. (D): Densitometric analysis of western blots indicate that expression levels of a-synuclein decreased
significantly in SN, increased significantly in hippocampus and were unaltered in FC of PQ-treated animals, compared to controls. b-Actin was
used as a reference control. Data are presented as mean ± SEM. (n = 3). Asterisks (*) represent significant differences, with p < 0.05 (Student’st -
test) in densitometric analyses. Magnification of IHC images is 40× and the scale bars = 40µm.
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indicated in Figure 10 and 11) indicate that neuroinflam-
mation is involved in PQ-mediated, ROS-induced dopami-
nergic neurodegeneration. There were also microglia-like,
large cellular structures in SN and hippocampus of PQ-
treated brain. Therefore, to evaluate involvement of micro-
glial cells in PQ-mediated neurotoxicity, the appearance of
microglial cells and expression levels of microglial markers
were assessed by immunofluorescence. We observed that
Iba1 immunoreactivity and expression levels significantly
increased in SN, but significantly decreased in FC with no
significant change in hippocampus, of PQ-treated animal
compared controls (Figure 13A, B, C and 13D). To assess
whether microglial cells appeared activated or not, we
evaluated the microglial activation marker Mac1. Western
blot analysis revealed that there was a significant increment
in Mac 1 expression in SN, but this was decreased signifi-
cantly in FC and no changes were observed in hippocam-
pus of PQ-treated brain compared controls (Figure 13D).
Supplementation with a-tocopherol in PQ-treated animals
did not reproduce any change in expression levels of Iba1
or of Mac 1 in any of the three regions of brain examined,
compared to PQ-treated mouse brain (data not shown).
Histological changes in microglial cells
To further assess microglia, we used Weil and Daven-
port’s method for microglia-specific silver staining [23],
applied to determine activation of microglial cells or
Figure 10 Differential patterns of IL-1b immunoreactivity in brain after PQ (10 mg/kg b.w.) treatment.I L - 1 b immunolocalization was
assessed in SN, FC and hippocampus (A, B and C respectively). Densitometric analysis of western blots for IL-1b (D) was performed to assess
expression levels for IL-1b in SN, FC and hippocampus. (A): IL-1b immunoreactivity is dispersed in SN of PQ-treated animals (b) compared to
controls (a). Immunoreactive deposits are found in a distinct population of small, rounded cells (putative microglia, black arrows) rather than
nucleated neuronal cells, in SN of PQ-treated animals, but not in controls. (B): A diffuse pattern of IL-1b immunoreactivity appeared in FC of PQ-
treated animal (d) with more intense immunoreaction compared to controls (c). (C): Both nucleated and non-nucleated areas of hippocampus
(dentate gyrus, CA3 and CA1; b, d, f respectively) of PQ-treated brain show more intense IL-1b immunoreactivity compared to controls (a, c and
e respectively). Nucleated areas of hippocampus of PQ-treated mice showed dense immunoreaction compared to non-nucleated areas (b, d and
f). (D): Densitometric analysis of western blots indicates that expression levels of IL-1b increased significantly both in FC and hippocampus
without any change in SN of PQ-treated animals, compared to controls. b-Actin was used as a reference control in western blots. Data are
presented as mean ± SEM (n = 3). Asterisks (*) represent significant differences at a level of p < 0.05 (Student’s t-test) for densitometric analses.
Magnification of IHC images is 40× and the scale bars = 40µm.
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Page 15 of 22microgliosis, as a priming event of neuroinflammation
(Figure 13). Microscopical observation revealed numer-
ous aggregations of microglial cells in SN, compared to
controls, and also changes in microglial morphology
(Figure 13E). Microglia were less apparent in FC of PQ-
treated brain compared to control (Figure 13F), and this
likely indicates microglial degeneration or microglial
migration. In hippocampus, aggregated microglial cells
were present in PQ-treated brain compared to control
mouse brain (Figure 13G).
Discussion
The cellular and molecular mechanisms underlying
PQ-induced neurodegeneration are unclear. Several
studies have indicated that PQ toxicity causes dopami-
nergic neuronal cell loss in SN and expression of a-
synuclein in SN as well as in FC through formation of
superoxide radicals. In this study, PQ-treated animals
showed several symptoms including impairment of
motor performances, which developed after two weeks
of treatment. These physiological changes are indica-
tive of PQ-mediated neurotoxicity. Dopaminergic neu-
r o n sa r em o r ev u l n e r a b l et o PQ-induced oxidative
stress than are other neuronal populations because
they are ill equipped to endure oxidative stress [37,38]
and because PQ promotes dopaminergic neuronal
death via a c-Jun-N-terminalk i n a s e3( J N K 3 ) - m e d i a t e d
cell signaling pathway [39]. SN is rich in dopaminergic
Figure 11 PQ (10 mg/kg b.w.) treatment increases TNF-a immunoreactivity in brain. TNF-a immunolocalization was assessed in SN, FC
and hippocampus (A, B and C respectively). Densitometric analyses of western blots for TNF-a (D) were performed to assess expression levels of
TNF-a in SN, FC and hippocampus. (A): TNF-a immunoreactivity was more intense in SN of PQ-treated animals (b) compared to controls (a).
TNF-a immunopositivity was found in both neuritic areas and in large, oval-shaped cells (putative microglia-macrophages, black arrows) in SN of
PQ-treated animals (b). (B): The FC of PQ-treated animals (b) showed more intense TNF-a immunoreactivity compared to controls (a).
Immunoreaction appeared in neurites and in small round cells (putative microglia, black arrows) in FC of PQ-treated animals (b). (C): TNF-a
immunoreactivity was found in both nucleated and non-nucleated areas of hippocampus, with more intense immunoreaction in hippocampal
regions of PQ-treated animals (dentate gyrus, CA3 and CA1; b, d and f respectively). TNF-a immunopositive small round cells (putative microglia,
black arrows) appeared in both nucleated and non-nucleated areas of hippocampus of PQ-treated animals (b, d and f). (D): Densitometric
analyses of western blots indicate that TNF-a expression levels increased significantly in all three regions (SN, FC and hippocampus) of PQ-
treated animals compared to controls. b-Actin was used as a reference control in western blots. Data are presented as mean ± SEM (n = 3).
Asterisks (*) represent significant differences at a level of p < 0.05 (Student’s t-test) for densitometric analyses. Magnification of IHC images is 40×
and the scale bars = 40µm.
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Page 16 of 22cells. Therefore, during PQ exposure, SN is the most
affected region of brain.
The hippocampal formation receives projections from
the midbrain’s dopaminergic cell groups and contains
mRNA for dopamine receptors [40], and FC receives
output from SN via the thalamus [41]. Previous studies
have shown that PQ deposition is found in hippocam-
p u sa sw e l la si nF C[ 4 2 , 4 3 ] .T h e r e f o r e ,a p a r tf r o mS N ,
PQ-mediated mitochondrial injury by oxidative stress
has a toxic influence on hippocampus and FC of mice
[18]. Therefore, along with SN, FC and hippocampus
were major areas of concern during PQ-mediated neu-
rotoxicity in the present study.
Multiple but sufficiently low doses of PQ are well tol-
erated by peripheral organs in rats without apparent
oxidative stress [44]. In the present study, ROS levels
increased (as reflected by high activity of ROS-scaven-
ging enzymes) significantly in three regions of brain
with PQ doses of 10 mg/kg b.w. or greater. However,
ROS levels in peripheral organs increased significantly
with all lethal doses (20 mg/kg b.w. to 80 mg/kg b.w.)
but not with a sublethal dose (10 mg/kg b.w.) in our
treatment regimen. Therefore, in our animal model,
impaired motor function appeared to be due to PQ-
induced, brain-specific ROS generation, which promotes
neurodegeneration, but not due to ROS generation in
peripheral organs. Hence, peripheral levels of ROS at a
PQ dose of 10 mg/kg b.w. may not be sufficient to
increase ROS levels in brain. We may consider that the
rise in ROS levels in brain with a PQ dose of 10 mg/kg
Figure 12 Tocopherol supplementation reduces PQ (10 mg/kg b.w.)-induced TNF-a overexpression. TNF-a immunolocalization in SN, FC
and hippocampus after PQ treatment with or without tocopherol supplementation (A, B and C respectively). Densitometric analyses of western
blots indicate that tocopherol supplementation reduced expression levels of TNF-a significantly in SN, hippocampus, and FC of PQ-treated
animals compared to PQ-treated animals without tocopherol. (A): TNF-a immunoreactivity of oval-shaped cells (microglia-macrophages)
appeared in SN after PQ treatment (a), and this was reduced by a-tocopherol (b). (B): TNF-a immunopositivity appeared in microglia-like cells in
FC after PQ treatment (a), and this was reduced by tocopherol (b). (C): TNF-a immunoreactivity appeared in both nucleated and non-nucleated
areas of hippocampal regions CA1, CA3, and dentate gyrus (a, c and e respectively) after PQ treatment (b, d and f respectively). PQ treatment
followed by tocopherol reduced TNF-a immunoreactivity in nucleated and non-nucleated areas of hippocampus (b, d and f respectively). (D):
Densitometric analyses of western blots indicate that PQ treatment increased TNF-a expression levels in SN, FC and hippocampus compared to
respective saline-treated control. Expression of TNF-a in the three regions remained unaltered after PQ treatment followed by tocopherol,
compared to controls. Tocopherol did not alter TNF-a expression compared to saline-treated controls. b-Actin was used as a reference control in
western blots. Data are presented as mean ± SEM. (n = 3). Asterisks (*) represents significant differeneces at a level of p < 0.05 (Student’s t-test)
for densitometric analyses. Magnification of IHC images is 40× and the scale bars = 40µm.
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Page 17 of 22Figure 13 Microglial activation after PQ (10 mg/kg b.w.) treatment. Iba 1 immunolocalization (microglial marker) in SN, FC and
hippocampus (A, B and C respectively; Weil and Davenport’s method – gray scale) in SN, FC and hippocampus (E, F and G respectively).
Densitometric analyses of western blots for Iba 1 and Mac1 (microglial activation marker) to assess expression levels in SN, FC and hippocampus
(D and H respectively): (A) intensity of Iba 1 immunofluorescence increased in SN of PQ-treated animals; (B, C) intensity of Iba 1
immunofluorescence decreased in FC (B) and hippocampus (C) of PQ-treated animals. (D) Densitometric analyses of western blots: Iba 1
expression increased significantly in SN, decreased in FC and remained unaltered in hippocampus of PQ-treated mice compared to vehicle-
treated controls. (E, F and G): Silver staining revealed a reactive phenotype for microglia (red arrow), which appeared in SN as aggregated forms
(b) in PQ-treated brain (E). Silver-impregnated microglia decreased in FC of PQ-treated animals (F). Aggregated forms of microglia appeared in
hippocampus (G) of PQ-treated brain, but not controls. (H) Densitometric analyses of western blots indicate that Mac1expression increased
significantly in SN, decreased significantly in FC and remained unchanged in hippocampus of PQ-treated animals. b-Actin was used as a
reference control in western blots. Data are presented as mean ± SEM (n = 3). Asterisks (*) represent significant differences at a level of p < 0.05
(Student’s t-test) for densitometric analyses. Magnification of immunofluorescence images is 10× and magnification of silver-stained images is
40×; the scale bars = 40 µm.
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Page 18 of 22b.w. is a local effect, and that ROS may be involved in
alteration of other parameters in brain. PQ needs time
to cross the blood-brain barrier to reach brain tissue
and generate ROS generation. As with other, higher,
lethal doses, the availability of PQ in brain may not be
sufficient to produce maximum toxicity. Such higher
doses of PQ may produce acute peripheral toxicity that
causes more severe peripheral tissue (e.g., lung, kidney,
etc.) damage (Bhattacharyya, unpublished) and our cell
counting data support this idea. Numbers of dopaminer-
gic cells decreased most significantly in SN at a sub-
lethal dose of PQ (10 mg/kg b.w.) compared to other
lower or lethal doses and to controls. Therefore, we
consider a dose of 10 mg/kg b.w. PQ as a sublethal dose
that may produce high levels of ROS locally in brain. a-
Tocopherol supplementation decreased ROS levels in all
three regions of brain.
Increased ROS levels induced differential changes in
cellular morphology in all three regions of brain in the
present study. Pyknotic nuclei appeared in SN, in FC
and in hippocampus of the treatment group, indicating
that, apart from SN, hippocampus and FC are also
affected by PQ-mediated neurotoxicity. Many Lewy
body-like structures in FC indicate that there might be
involvement of differential a-synuclein expression level
not only in FC but also in SN and hippocampus. PQ
exposure induced the formation of a-synuclein-contain-
ing deposits. This effect, however, was seen in both con-
trol and a-synuclein-overexpressing mice, thus
suggesting that neuroprotection is not a mere conse-
quence of lack of protein deposition. a-Synuclein itself
may possess properties that counteract toxic injury, and
its expression could affect specific stress signaling path-
ways linked to neuronal survival. For example, Hashi-
moto and colleagues [45]have suggested that a-
synuclein expression can confer resistance to in vitro
hydrogen peroxide toxicity via inactivation of c-Jun N-
terminal kinase, a member of the mitogen-activated pro-
tein kinase family. This indicates that a-synuclein over-
expression protects against Paraquat-induced
neurodegeneration. a-Synuclein is not only a compo-
nent of Lewy bodies and synapses but also of axons, and
aggregated a-synuclein might interfere with axonal
transport and lead to cell death [46]. Microscopical
observations show that increased immunoreactivity for
a-synuclein is predominant in FC of PQ-treated brain
in our studies. However, a-synuclein protein expression
levels do not change significantly in FC of PQ-treated
mouse brain. Expression of a-synuclein did increase sig-
nificantly in hippocampus, whereas expression levels of
a-synuclein decreased in SN of our treated group. As in
SN, cell death was more pronounced, suggesting that
decreased a-synuclein levels indicate earlier degenera-
tion in SN than in the other two regions of brain. In
hippocampus, for example, a-synuclein levels increased
to protect neuronal cells. Previous reports have stated
that methylation of human a-synuclein gene intron 1
decreases that gene’s expression, while inhibition of
DNA methylation activates a-synuclein gene expression.
On the other hand, extensive neuronal expression of a-
synuclein and disruption of a-synuclein function or
abnormal aggregation may have similarly widespread
consequences [47]. Therefore, the reduced expression of
a-synuclein in SN, increased expression in hippocam-
pus, and aggregated forms in FC found in our present
study might correlate with the a-synuclein gene poly-
morphism associated with PQ-mediated neurotoxicity in
this mouse model and the differential time frames
necessary to initiate neurodegeneration in these different
regions.
In relation to the hypothesis that differential a-synu-
clein expression may modulate TH expression levels, we
evaluated TH-positive neuronal vulnerability in all three
regions of PQ-treated mouse brain. We observed that
expression levels of TH decreased in all three regions of
PQ-treated mouse brain. The reduction of TH expres-
sion may indicate a reordering of protein biosynthesis
favoring production of protein required for axonal
regeneration at the expense of those involved in neuro-
transmission [48]. The most interesting observation is
that the distribution of TH immunoreactivity changes
from nucleated areas to non-nucleated areas in hippo-
campus and FC, but not in SN. Hence, we may predict
that TH, which is present in axons (non-nucleated
areas) shows greater immunoreactivity in non-nucleated
areas compared to nucleated areas in hippocampus and
FC under our treatment conditions. The presence of
pyknotic nuclei in SN may explain in part the total
reduction of TH in SN. However, the exact cause of
such differential patterns of TH expression in three
brain regions under our treatment conditions needs
further investigation. Dopaminergic immunoreactivity
decreased primarily in SN and FC, while in hippocam-
pus no significant changes were observed. At the same
time, there might be neuronal compensatory mechan-
isms involved to regenerate new dopaminergic neurons
such that overall levels of DOPA decarboxylase and
FOX3 expression level do not change.
In the present study, differential expression patterns of
a-synuclein and TH due to PQ treatment elicited high
expression levels of proinflammatory cytokines such as
TNF-a in the three regions of mouse brain, and of IL-
1b in FC and hippocampus of mouse brain. There
might be involvement of activated microglial cells in
promoting neuroinflammation. Microglial cells in a rest-
ing state continuously maintain homoeostatic activity in
the CNS, and in a fully activated phagocytic state micro-
glial cells scavenge neurotoxins, remove dying cells and
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Page 19 of 22cellular debris, and secrete trophic factors that promote
neuronal survival, reorganization of neuronal circuits
and repair [49,50]. Insufficient clearance by microglia is
prevalent in several neurodegenerative diseases and in
normal ageing [51]. Over-activation of microglia may
cause alterations in immunophenotypic expression and
inflammatory profile (promoting microglia senescence),
and that condition may switch microglial function from
neuroprotective to neurotoxic effects [52]. Increased
expression of Mac1 (microglial activation marker) in SN
indicates chronic neuroinflammation. However
decreased expression of Iba1 (a microglial marker) and
Mac 1 with increased cytokine levels in FC might reflect
the peripheral supply of cytokines without local produc-
tion by microglial cells in brain.
Long-standing activation of microglia during chronic
neuroinflammation causes sustained release of inflam-
matory mediators that promote activation of additional
microglial proliferation, and further release of inflamma-
tory factors [53]. In search of involvement of microglial
cells in PQ-mediated neurotoxicity; we have found
aggregated microglial cells in SN of PQ-treated mouse
brain, while microglia-specific staining is less positive in
FC. Although there are aggregated microglial cells in
hippocampus of treated mouse brain, microglial cell-
specific staining decreases compared to controls in hip-
pocampus. At this point it is not clear whether micro-
glial cells degenerate or migrate to other areas with
pathogenic lesioning. Chemokines regulate rapid migra-
tion of microglia to injury sites in CNS and amplify neu-
roinflammation [54]. If microglial cells degenerate, then
this degeneration presumably relates to a failure of neu-
roprotective functions and subsequent contributions to
neurodegeneration [55]. Recent studies indicate that
death of microglial cells may occur as a consequence of
overproduction of immuno-inflammatory molecules
along with production of anti-inflammatory molecules
such as IL-13, activation of Fas-mediated apoptotic sig-
naling, and/or toxins produced by over-activated micro-
glial cells themselves [56,57]. Although microglial
phenotypic shifting, as seen in our study, occurs in fron-
tal cortex and hippocampus, we found significant high
levels of inflammatory molecules in all three regions of
brain. Proinflammatory cytokines released from over-
activated microglia may act on the endothelium of BBB
cells to stimulate upregulation of adhesion molecules for
passage of T cells and monocytes that then go on to
release more cytokines. This indicates that chronic
inflammation may cause an increase in permeability of
the BBB [58-61]. From this point of view, we may pre-
dict that the high levels of pro-inflammatory/inflamma-
tory molecules in the three regions of brain found in
our present study may participate in increasing a per-
ipheral supply of inflammatory responses to those areas
of brain. Further investigation is needed to explore these
phenomena. As a-tocopherol supplementation
decreased TNF-a levels in all three regions of PQ-trea-
ted mouse brain, ROS-induced TNF-a production
might initiate neuroinflammation with or without invol-
vement of microglial cells during PQ treatment. Other
parameters, such as a-synuclein, dopaminergic neuronal
status and microglial status, were not altered with a-
tocopherol supplementation in PQ-treated brain. To
maintain the same time frame of sacrifice as PQ-treated
mice (day 7 after the last dose of PQ), we supplemented
different sets of PQ-treated mice with five doses of a-
tocopherol only. Therefore, further study is needed to
evaluate the effects of a-tocopherol supplementation in
PQ-treated mice brain for prolonged time spans.
Conclusion
We conclude that PQ-mediated neurotoxicity acts
mainly via ROS generation with involvement of differ-
ential expression patterns for a-synuclein in SN, FC
and hippocampus of mouse brain. Neuroinflammation
took place with or without involvement of microglial
activation during PQ treatment and dopaminergic neu-
ronal status changed differentially. Involvement of
these differential changes might indicate separate sig-
naling phenomena and different time frames for initia-
tion of neurodegeneration in SN, FC and hippocampus
of mouse brain due to PQ treatment. The exact cause
of such changes and their correlation need further
study.
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